Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Thorac Oncol. 2013 Feb;8(2):179–184. doi: 10.1097/JTO.0b013e3182779d18

Figure 2.

Figure 2

Activity of different systemic treatment approaches against advanced NSCLC harboring an EGFR exon 20 insertion. Treatment settings studied are treatment with erlotinib, treatment with combination chemotherapy, and treatment with subsequent cytotoxic chemotherapy. Patients treated in multiple settings are included in each setting studied, therefore no statistical comparison is performed. (A) Waterfall plots show maximal tumor shrinkage. Bars marked with asterisks represent non-quantifiable progression (i.e. non-target disease or new lesions). (B) Time to treatment failure.